Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/19/2012CA2539469C Pyridylacetylenes for use as radiotracers and imaging agents
06/19/2012CA2536666C Modafinil modified release pharmaceutical compositions
06/19/2012CA2529377C Compositions for improved oxidative status in companion animals
06/19/2012CA2524179C A composition and its use for adminstration of mitomycin c in vivo for treating a multi-drug resistant tumor
06/19/2012CA2523439C Pyrimidine derivatives useful for the treatment of diseases mediated by crth2
06/19/2012CA2522784C Antiandrogens with marginal agonist activity and methods of use
06/19/2012CA2512563C Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
06/19/2012CA2504448C Transcription factor modulating compounds and methods of use thereof
06/19/2012CA2495417C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
06/19/2012CA2491943C Epothilone derivatives for the treatment of cancer
06/19/2012CA2471043C Stable surfactant compositions for suspending components
06/19/2012CA2469939C Method of inducing ovulation using a non-polypeptide camp level modulator
06/19/2012CA2398432C Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
06/19/2012CA2319872C Pharmaceutical composition for the treatment of hepatocellular carcinoma
06/19/2012CA2311166C Nucleic acids involved in the responder phenotype and applications thereof
06/14/2012WO2012079092A2 Testosterone undecanoate compositions
06/14/2012WO2012079079A1 Production of induced pluripotent stem cells
06/14/2012WO2012079075A1 Deuterated phthalimide derivatives
06/14/2012WO2012079072A2 Subcutaneously infusible levodopa prodrug compositions and methods of infusion
06/14/2012WO2012079058A2 Use of jasmonate to treat bladder dysfunction
06/14/2012WO2012079057A2 Use of jasmonate for improving skeletal muscle function
06/14/2012WO2012079043A2 Targeting kidney mesangium with nanoparticles of defined diameter
06/14/2012WO2012079035A1 Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
06/14/2012WO2012079032A2 Compositions and methods of treating drug-resistant retroviral infections
06/14/2012WO2012079024A2 Implantable devices coated with insulin-mimetic agent composites and methods thereof
06/14/2012WO2012079022A1 Substituted dioxopiperidinyl phthalimide derivatives
06/14/2012WO2012079020A2 Compounds that modulate store operated calcium channels
06/14/2012WO2012079017A1 Hydroxylated tricyclic compounds
06/14/2012WO2012078999A1 Compositions for treating dermatitis and ichthyosis, and methods for treating dermatitis and ichthyosis
06/14/2012WO2012078994A1 Imidazo [1, 2-a] pyridine sulfonamides as trpm8 modulators
06/14/2012WO2012078992A1 Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto
06/14/2012WO2012078980A2 Compositions, methods and kits for remineralization and inhibition of dental caries in teeth
06/14/2012WO2012078915A1 Macrocyclic inhibitors of flaviviridae viruses
06/14/2012WO2012078909A1 Thiazolpyrimidine proteostasis regulators
06/14/2012WO2012078902A2 Proteostasis regulators
06/14/2012WO2012078874A1 Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012WO2012078869A1 Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012WO2012078868A1 Methods for the preparation of charged crosslinkers
06/14/2012WO2012078867A2 Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012WO2012078859A2 Protein kinase d inhibitors
06/14/2012WO2012078855A1 Substituted pyrazolopyrimidines as glucocerebrosidase activators
06/14/2012WO2012078844A1 Hiv integrase inhibitors
06/14/2012WO2012078834A1 Hiv integrase inhibitors
06/14/2012WO2012078832A1 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
06/14/2012WO2012078831A2 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
06/14/2012WO2012078817A1 Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
06/14/2012WO2012078805A1 Polycyclic lpa1 antagonist and uses thereof
06/14/2012WO2012078797A1 Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products
06/14/2012WO2012078777A1 Bicyclic compounds as pim inhibitors
06/14/2012WO2012078771A1 Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
06/14/2012WO2012078757A2 Combination breast cancer therapy with hsp90 inhibitory compounds
06/14/2012WO2012078746A2 Compositions and methods for mobilizing stem cells
06/14/2012WO2012078708A1 Combination comprising methotrexate and an antifolate compound
06/14/2012WO2012078703A2 Inhibiting chromosome instability in ovarian cancer
06/14/2012WO2012078695A2 Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
06/14/2012WO2012078687A1 Substituted pyrimidine urea compounds
06/14/2012WO2012078684A1 Substituted pyridinone-pyridinyl compounds
06/14/2012WO2012078674A1 Substituted indole/indazole-pyrimidinyl compounds
06/14/2012WO2012078673A1 Substituted pyridine urea compounds
06/14/2012WO2012078667A2 Compositions and methods relating to proliferative diseases
06/14/2012WO2012078647A2 Chemical composition to detect and treat amyloid in a patient's brain and retina
06/14/2012WO2012078633A2 Methods of inhibiting metastasis from cancer
06/14/2012WO2012078605A1 Topical combination formulations of macrocyclic lactones with synthetic pyrethroids
06/14/2012WO2012078593A2 Lysophosphatidic acid receptor antagonists and uses thereof
06/14/2012WO2012078591A1 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
06/14/2012WO2012078586A2 Pharmaceutical composition comprising nanog shrna, and method of usnig nanog shrna to treat cancer
06/14/2012WO2012078574A2 Janus kinase 2 (jak2) inhibitor for the treatment of lupus
06/14/2012WO2012078559A2 Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
06/14/2012WO2012078546A2 Compositions and methods for stabilizing ingredients using 2,4-pentanedione compounds
06/14/2012WO2012078545A1 Benzofurane derivatives for the treatment of hepatitits c
06/14/2012WO2012078525A2 Compositions and methods for treating ophthalmic conditions
06/14/2012WO2012078519A2 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
06/14/2012WO2012078504A1 TREATMENT OF CHRONIC INFLAMMATION WITH A 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVE
06/14/2012WO2012078492A1 A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
06/14/2012WO2012078448A1 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
06/14/2012WO2012078416A2 Monophosphate prodrugs of dapd and analogs thereof
06/14/2012WO2012078405A2 Methods and compositions for regulating gastric emptying
06/14/2012WO2012078358A1 Compositions and methods for nutrient delivery
06/14/2012WO2012078210A1 Crth2 modulators and preparation thereof
06/14/2012WO2012078155A1 Nitric oxide and its biomedical significance
06/14/2012WO2012078135A1 Oral care compositions comprising a quinone and a further antimicrobial agent
06/14/2012WO2012078121A2 Solid oral dosage form comprising cefdinir
06/14/2012WO2012078072A1 Medicinal preparation, method for producing the medicinal preparation and method for the use thereof
06/14/2012WO2012077968A2 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
06/14/2012WO2012077932A2 Novel pyrazole pyridine derivative or pharmaceutically acceptable salts thereof, method for producing same, and pharmaceutical composition including same
06/14/2012WO2012077828A1 Therapeutic agent for inflammatory diseases, which can inhibit function of inflammatory cytokine
06/14/2012WO2012077783A1 Novel depsipeptide pf1442 substance and process for production thereof
06/14/2012WO2012077775A1 Composition for treatment of cancer pain and use thereof
06/14/2012WO2012077696A1 Stabilizer of acetaminophen
06/14/2012WO2012077655A1 Spiro derivative having gpr119 agonist activity
06/14/2012WO2012077651A1 Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
06/14/2012WO2012077622A1 Therapeutic or prophylactic agent for keloid or hypertrophic scar, and agent for inhibiting tissue hypertrophy in injured part of airway
06/14/2012WO2012077133A1 Processes for preparation of montelukast sodium and purification of diol intermediate
06/14/2012WO2012077127A1 A protein free surfactant composition for pulmonary diseases and a process for preparing the same
06/14/2012WO2012077108A1 Multifunctional nitroxide derivatives and uses thereof
06/14/2012WO2012077051A1 Hydroxylated aminotriazole derivatives as alx receptor agonists
06/14/2012WO2012077049A1 Oxazolyl-methylether derivatives as alx receptor agonists
06/14/2012WO2012077031A1 Substituted imidazoquinoline derivatives
06/14/2012WO2012077002A2 Melt processed antimicrobial composition
06/14/2012WO2012076988A1 A complex of garcinol, cyclodextrin and method thereof
1 ... 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 ... 7860